Aims-To determine cell proliferation in infiltrating breast carcinomas. Methods-Using the MIB-1 monoclonal antibody, the proliferation index was measured in paraffin wax sections of 871 breast cancers. The MIB-1 proliferation index was compared with other markers of disease progression: size, lymph node status, histotype, oestrogen and progesterone receptor status, expression of p53 and Neu, and DNA ploidy. AUl parameters were measured using image analysis. In 347 tumours, the MIB-1 and Ki-67 proliferation indexes were compared. Follow up data were available for 170 cases (median 66.5 months). Results-Of the tumours, 314 (36%) had a high proliferation index. The MIB-1 proliferation index was correlated directly with size, nodal status, overexpression of p53 and Neu, and the DNA index; and inversely with oestrogen and progesterone receptor status. The correlation between MIB-1 and Ki-67 proliferation indexes was statistically significant. In patients with pT1 tumours, a low proliferation index correlated with a longer relapse-free interval and overall survival; node negative patients with a low proliferation index had a longer overall survival. Conclusions-The MIB-1 proliferation index is a reliable, practical and useful method ofmeasuring proliferative activity and is an important predictor of clinical behaviour. ( Clin Pathol 1996;49:926-930) Keywords: breast cancer, MIB-1, proliferative activity, image analysis, overall survival.
Use of immunocytochemistry to measure tumour proliferation preserves both cytological and architectural features and can be used to detect proliferation related nuclear antigens, one of the most important of which is Ki-67. The Ki-67 nuclear antigen is expressed by dividing cells in all phases of the cell cycle except Go 1 and has been established as an independent prognostic marker in breast cancer. Unfortunately, detection of Ki-67 is limited to frozen tissue only. However, several antibodies are available for quantifying cell proliferation in paraffin wax embedded specimens, including antibodies directed against proliferating cell nuclear antigen (PCNA) and the Ki-Sl and MIB-1 monoclonal antibodies."'' MIB-1, in particular, recognises Ki-67 nuclear antigen, permitting the assessment of growth fraction on small tumours, formalin fixed tissue and retrospective studies on archival material.
The aim of the present study was to measure the MIB-1 proliferation index in 871 infiltrating breast carcinomas. The results were compared with other markers of prognosis: oestrogen and progesterone receptor status, overexpression of c-erbB-2/Neu and p53, the DNA index, and the Ki-67 proliferation index. The clinical usefulness of the MIB-1 proliferation index was also evaluated in 170 patients (median follow up 66.5 months).
Methods
Paraffin wax blocks of 871 infiltrating primary breast cancers were retrieved from the archives. The clinicopathological details of the patients studied are presented in The MIB-1, Ki-67, Ab-1, and D07 antibodies were detected using the avidin-biotinperoxidase complex (ABC) method (Vectastain ABC kit; Vector Laboratories, Burlingame, California, USA). 3,3'Diaminobenzidine tetrahydrochloride (Sigma) was used as the chromogen; ethyl green was used for nuclear counterstaining, as described by the manufacturer (Cell Analysis Systems, San Jose, California, USA).
DNA index
Touch imprints were dried in air for one hour, fixed in 10% buffered formalin for 30 minutes and stained by the Feulgen method using a commercially available kit (Quantitative DNA stain, Cell Analysis Systems).
IMAGE ANALYSIS
The proliferation index (MIB-1/Ki-67), oestrogen and progesterone receptor status, p53, Neu, and DNA ploidy were quantified using an image analysis system (CAS 200; Becton Dickinson, San Jose, California, USA).'2 The percentage of positively stained nuclei (proliferation index, oestrogen and progesterone receptor and p53) and plasma membranes (Neu) was recorded. The use of an interactive window command allows the operator to select the fields containing infiltrating carcinoma cells and to exclude areas with non-neoplastic components. For each tumour section, at least 25 microscopic fields, including peripheral and central areas of invasive carcinoma (40x objective), were measured. At >15 fields of vision, the positive nuclear area (PNA) has a low SD and a stable coefficient of variation." For the proliferation index, at least 2000 nuclei were assessed in order to reduce the margin of error expected. '4 Ten per cent of positive area was used as cut-off value for oestrogen receptor, progesterone receptor and Neu; 5% was used for p53; 13% of proliferation index representing the second tertile in distribution was used as cut-off value to divide cases with a low and high proliferative activity. The cut-off values selected were similar to those used in other studies.'2 15 16 For DNA ploidy 200-250 neoplastic cells for each tumour imprint were analysed and compared with calibration cells, which contained a known amount of DNA. The DNA content was determined by the quantitation of the optical density of each Feulgen stained nucleus. DNA distribution histograms were generated. The DNA index (the modal peak of DNA distribution) was assumed as the index of tumour ploidy; values between 0.9 and 1.1 were considered diploid.
STATISTICAL ANALYSIS
The relations between the MIB-1 proliferation index and other pathobiological variables were investigated using non-parametric Spearman's rank correlation tests and the Mann Whitney U test. Follow up analysis of the relapse-free interval and overall survival was performed using the actuarial model and Lee-Desu statistics.'7 Significance was set at p < 0.05. Eighty per cent of tumours were aneuploid. When the distribution of the MIB-1 proliferation index was assessed according to age, younger patients (group 1) had tumours with higher proliferative activities (54.9%) than patients in groups 2/3 (38.5% and 34%; p = 0.009).
The MIB-1 proliferation index was correlated directly with size (rs = +0. 30 The Ki-67 and MIB-1 proliferation indexes were compared in 347 cases: the Ki-67 proliferation index ranged from 0.01% to 87.7% PNA (median 5.1% PNA) and MIB-1 proliferation index ranged from 0.58% to 94.1 % PNA (median 11 % PNA).
There was a good correlation between the MIB-1 and Ki-67 proliferation indexes (rs = +0.73, p < 0.001; fig 1) . Discordant values were observed in 70 cases. In 68 the MIB-1 proliferation index was higher (table 3) .
The usefulness of the MIB-1 proliferation -P1<13% (OS) index as a predictor of clinical outcome was 
